The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to compare the 3-year disease-free survival of dose-dense
epirubicin and cyclophosphamide followed by paclitaxel with paclitaxel plus carboplatin as
adjuvant therapy for triple-negative breast cancer with homologous recombination repair
deficiency.
The other purpose of this trial is to observe the patient's tolerance.